Prostate Cancer WisdomCard &trade;

Cancer Research UK Health Organization

Why today’s prostate drug decision makes no sense : Cancer Research UK - Cancer Research UK - Science Update blog

scienceblog.cancerresearchuk.org — “Why today’s prostate drug decision makes no sense : Cancer Research UK - Cancer Research UK - Science Update blog” View full resource at scienceblog.cancerresearchuk.org

Most Recently Shared on February 2, 2012 at 7:00 am By:

Read more about why we think today’s decision on #prostate cancer drug #abiraterone is wrong: http://t.co/PNimAXzU

1 week ago...

Cancer Research UK Health Organization

Prostate cancer NICE decision 'makes no sense' : Cancer Research UK

info.cancerresearchuk.org — “Cancer Research UK is urging a solution to the impasse over the advanced prostate cancer drug abiraterone, which has been turned down by NICE.” View full resource at info.cancerresearchuk.org

Most Recently Shared on February 2, 2012 at 12:10 am By:

#Prostate cancer NICE decision ‘makes no sense’ - press release: http://t.co/Rh2Z9XhI

1 week ago...

About Us

fhcrc.org — “About Us” View full resource at fhcrc.org

Most Recently Shared on January 31, 2012 at 8:31 pm By:

Hutchinson Center Research and Hospital

RT @fhcrc_events: Last day to RSVP to the prostate cancer symposium on Feb. 4! http://t.co/LXPgJ3Yo

Urology Medical Article | Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer

mdlinx.com — “Urology Medical Article: Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic Prostate Cancer” View full resource at mdlinx.com

Most Recently Shared on January 27, 2012 at 3:04 pm By:

Sandeep Pulim MD Doctor, Health Communicator, and Physician

Prediction of Response to Androgen Deprivation Therapy and Castration Resistance in Primary Metastatic ... http://t.co/BCjxH4q1 #urology

Data on Watchful Waiting for Low-risk Prostate Cancer May Swing Focus to Higher-risk Tumors and Quality of Life - The ASCO Post

ascopost.com — “Data on Watchful Waiting for Low-risk Prostate Cancer May Swing Focus to Higher-risk Tumors and Quality of Life - The ASCO Post” View full resource at ascopost.com

Most Recently Shared on January 27, 2012 at 2:09 pm By:

The ASCO Post Health Magazine, Hematology, and Oncology

Data on Watchful Waiting for Low-risk #ProstateCancer May Swing Focus to Higher-risk Tumors and Quality of Life http://t.co/33eNF2S1

News-Medical.Net Health News

GUMC licenses worldwide rights of 'theranostic' to BioMetrx

news-medical.net — “Georgetown University Medical Center (GUMC) has licensed worldwide rights of a potential novel cancer therapy and diagnostic, or "theranostic," to BioMetrx, LLC. The agent was invented by two Georgetown researchers.” View full resource at news-medical.net

Most Recently Shared on January 25, 2012 at 11:37 am By:

Prostate Cancer: GUMC licenses worldwide rights of 'theranostic' to BioMetrx: Georgetown University Medical Cent... http://t.co/5nIDkE1V

Drug May Slow Early Prostate Cancer: Study

health.yahoo.net — “TUESDAY, Jan. 24 (HealthDay News) -- New research suggests that Avodart, a drug used to treat an enlarged prostate gland, may help slow the progression of early stage prostate cancer, reducing the need for aggressive treatment in some men.” View full resource at health.yahoo.net

Most Recently Shared on January 25, 2012 at 6:18 am By:

Jennifer Ann Grisso Nurse and Active Health Library

Drug May Slow Early Prostate Cancer: Study: TUESDAY, Jan. 24 (HealthDay News) -- New research suggests that Avod... http://t.co/jUM5eixT

News-Medical.Net Health News

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

news-medical.net — “Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.” View full resource at news-medical.net

Most Recently Shared on January 25, 2012 at 5:30 am By:

Prostate Cancer: Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion: Johnson & Johnson today ... http://t.co/6JIr8MJi

IVD Technology Health Magazine

Opko Health Acquires Next Generation Prostate Cancer Tests | IVD Technology

ivdtechnology.com — “Opko Health Inc. announced the acquisition of an exclusive license from Arctic Partners Ab Oy (Turku, Finland) for two biomarkers in the kallikrein family which, used together with prostate specific antigen (PSA), can reduce the need for prostate biopsies by over 50%. These novel biomarkers were developed by investigators at the University of Malmo, Sweden, University of Turku, Finland, and Memorial Sloan Kettering Cancer Center, New York.” View full resource at ivdtechnology.com

Most Recently Shared on January 24, 2012 at 7:02 pm By:

Opko Health Acquires Next Generation Prostate Cancer Tests http://t.co/1HtLchVt

3 weeks ago...

Urology & Nephrology OW Health

Drug May Slow Early Prostate Cancer: Study --Doctors Lounge

doctorslounge.com — “Drug May Slow Early Prostate Cancer: Study --Doctors Lounge” View full resource at doctorslounge.com

Most Recently Shared on January 24, 2012 at 3:12 pm By:

Drug May Slow Early Prostate Cancer: Study: Typically used for an enlarged prostate, it could prevent need for a... http://t.co/LUa2uxN8

3 weeks ago...

Drug May Slow Early Prostate Cancer: Study - Yahoo! News

news.yahoo.com — “From Yahoo! News: TUESDAY, Jan. 24 (HealthDay News) -- New research suggests that Avodart, a drug used to treat an enlarged prostate gland, may help slow the progression of early stage prostate cancer, reducing the need for aggressive treatment in some men.” View full resource at news.yahoo.com

Most Recently Shared on January 24, 2012 at 2:42 pm By:

john clay mchugh Doctor, Surgeon, Urologist, and Physician

Drug May Slow Early Prostate Cancer: Study: TUESDAY, Jan. 24 (HealthDay News) -- New research suggests that Avod... http://t.co/cLzxFqhL

3 weeks ago...